论文部分内容阅读
目的:研究奈达铂和顺铂在局部晚期宫颈癌新辅助化疗中的疗效和安全性。方法:58例巨块型局部晚期宫颈癌患者行新辅助化疗,奈达铂化疗组32例与顺铂化疗组26例均行2～3疗程静脉化疗,观察两组疗效及不良反应。结果:奈达铂组和顺铂组有效率分别为65.63%和61.54%,差异无统计学意义(P>0.05)。奈达铂组胃肠道毒性、肾毒性明显低于顺铂组(P<0.05),两组肺毒性、神经毒性、过敏反应及血液毒性(包括白细胞减少、贫血、血小板减少)无明显差异(P>0.05)。结论:奈达铂可应用于局部晚期宫颈癌新辅助治疗,值得进一步研究其临床价值。
Objective: To study the efficacy and safety of nedaplatin and cisplatin in neoadjuvant chemotherapy for locally advanced cervical cancer. Methods: Neoadjuvant chemotherapy was given in 58 cases of massive locally advanced cervical cancer. Intravenous chemotherapy was given in 32 cases in nedaplatin group and 26 cases in cisplatin chemotherapy group. Efficacy and side effects of two groups were observed. Results: The efficacies of nedaplatin group and cisplatin group were 65.63% and 61.54%, respectively, with no significant difference (P> 0.05). Gastrointestinal toxicity and nephrotoxicity in nedaplatin group were significantly lower than those in cisplatin group (P <0.05). There was no significant difference in pulmonary toxicity, neurotoxicity, anaphylaxis and hematologic toxicity (including leukopenia, anemia and thrombocytopenia) P> 0.05). Conclusion: Nedaplatin can be used in neoadjuvant treatment of locally advanced cervical cancer, and its clinical value deserves further study.